InvestorsHub Logo
Followers 32
Posts 5818
Boards Moderated 0
Alias Born 05/23/2006

Re: cjgaddy post# 312285

Thursday, 09/21/2017 6:28:09 AM

Thursday, September 21, 2017 6:28:09 AM

Post# of 346721
Poster comparisons... SITC 2017 vs SITC 2016

Author differences:

Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma

2017 Poster

Sadna Budhu1, Rachel Giese1, Olivier De Henau1, Roberta Zappasodi1, Luis Felipe Campesato1, Aditi Gupta1, Christopher Barker1, Bruce Freimark2, Jedd D. Wolchok1, Taha Merghoub1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Peregrine Pharmaceuticals, Inc., Tustin, CA, USA

2016 Poster

Sadna Budhu1 , Olivier De Henau 1 , Roberta Zappasodi 1 , Kyle Schlunegger 2 , Bruce Freimark 2 , Jeff Hutchins 2 , Christopher A. Barker 3 , Jedd D. Wolchok 1 and Taha Merghoub 1

Checkpoint blockade | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Solid tumors

New Authors on Poster https://www.mskcc.org/research-areas/labs/jedd-wolchok

Rachel Giese MD
Tumors can be recognized by the immune system through their ability to make certain proteins that are not present in normal cells, called neoantigens. I am working to identify CD8+ T cells that recognize these neoantigens, in cancer patients using a combinatorial multimer technology. If we can identify relevant neoantigens, we may be able to augment tumor rejection by the immune system. In addition, I am working on a mouse model of oral cavity carcinoma to study the role of inflammation induced by bacteria in the mouth and the to response to immunotherapy.

Luis Felipe Campesato Phd
My aim is to investigate the immunosuppressive network existent in the tumor microenvironment. In particular, my research focuses on exploring the crosstalk between tumor cells and suppressive myeloid cells, and how that interaction affects T cell-mediated immunity. Based on these findings I will develop means to overcome immune suppression and generate more efficient antitumor immunity.

Aditi Gupta
Gupta will study the expression pattern of a protein called TGF beta in melanoma, working to characterize whether inhibiting TGF beta prevents cancer growth. Gupta will be mentored by Memorial Sloan Kettering Cancer Center investigators Dr. Jedd Wolchok, the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation and chief of the Melanoma and Immunotherapeutics Service, and Dr. Taha Merghoub, co-director of the Ludwig Collaborative Laboratory and the Swim Across America Laboratory.

https://news.weill.cornell.edu/news/2017/04/five-weill-cornell-medical-students-win-prestigious-howard-hughes-fellowships


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News